Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin (biologic) presented as an injectable solution for subcutaneous use. It provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to support ovarian follicular development and ovulation in women with infertility. GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menopur is used in reproductive medicine to address disorders of ovarian function and to support assisted reproductive technologies. - Infertility due to anovulation: stimulates follicular growth and induces ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for IVF: enhances the number of mature oocytes retrieved during in‑vitro fertilisation cycles. - Hypogonadotropic hypogonadism: provides exogenous FSH and LH activity to trigger ovulation in women with deficient gonadotropin secretion.

Menopur may cause a range of adverse reactions, most of which are related to ovarian stimulation and injection site responses.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Ovarian hyperstimulation syndrome (mild): abdominal bloating, mild weight gain. - Nausea or vomiting: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Mood changes: irritability or emotional lability.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Ovarian torsion: acute pelvic pain requiring surgical intervention. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: implantation outside the uterine cavity.

Before initiating Menopur therapy, clinicians should assess patient suitability and monitor response closely. - Baseline ovarian assessment: perform ultrasound to evaluate follicle count and size. - Monitor estradiol levels: regular blood tests to detect excessive stimulation. - Adjust dose as needed: titrate based on follicular response and estradiol trends. - Contraindications: avoid in patients with ovarian cysts, uncontrolled thyroid disease, or active malignancy. - Patient counseling: inform about symptoms of ovarian hyperstimulation syndrome and when to seek medical attention. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur may interact with other medications that affect ovarian response or hormone metabolism.

Major Interactions (Avoid): - GnRH antagonists used concurrently without proper protocol: may blunt intended ovarian stimulation. - High‑dose estrogen therapy: can suppress endogenous gonadotropin release.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased risk of thromboembolic complications in ovarian hyperstimulation. - Thyroid hormone replacement: altered dosing may be needed due to changes in hormone binding. - Corticosteroids: may affect ovarian response and fluid balance.